Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer.
Kusama H, Kittaka N, Soma A, Taniguchi A, Kanaoka H, Nakajima S, Oyama Y, Seto Y, Okuno J, Watanabe N, Matsui S, Nishio M, Fujisawa F, Honma K, Tamaki Y, Nakayama T. Kusama H, et al. Among authors: nakayama t. Breast Cancer. 2023 Nov;30(6):1085-1093. doi: 10.1007/s12282-023-01504-y. Epub 2023 Oct 2. Breast Cancer. 2023. PMID: 37782377
Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N, Nakayama T, Kajita M, Miyake T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y, Noguchi S. Yamamoto N, et al. Among authors: nakayama t. Breast Cancer Res Treat. 2012 Feb;132(1):165-73. doi: 10.1007/s10549-011-1575-2. Epub 2011 May 19. Breast Cancer Res Treat. 2012. PMID: 21594664
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, Terashima M, Miyazaki M, Okamoto I, Nishida Y, Tominaga S, Tokunaga Y, Yamaguchi M, Sakamoto J, Nakayama T, Nakagawa K. Hayashi H, et al. Among authors: nakayama t. Breast Cancer. 2013 Apr;20(2):131-6. doi: 10.1007/s12282-011-0316-z. Epub 2011 Nov 29. Breast Cancer. 2013. PMID: 22124996 Clinical Trial.
Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy.
Tsunashima R, Naoi Y, Kishi K, Baba Y, Shimomura A, Maruyama N, Nakayama T, Shimazu K, Kim SJ, Tamaki Y, Noguchi S. Tsunashima R, et al. Among authors: nakayama t. Cancer Lett. 2012 Nov 1;324(1):42-7. doi: 10.1016/j.canlet.2012.04.017. Epub 2012 Apr 27. Cancer Lett. 2012. PMID: 22546287 Clinical Trial.
5,208 results